Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96


Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.

Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR.

Clin Cancer Res. 2008 Jul 15;14(14):4584-92. doi: 10.1158/1078-0432.CCR-07-5211.


BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ.

Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.


BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.

Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.


The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM.

Curr Biol. 2007 Feb 20;17(4):304-15. Epub 2007 Feb 8.


BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.


Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis.

Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P.

Cancer Immun. 2006 Jul 31;6:10.


Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin.

Rupp C, Dolznig H, Puri C, Schweifer N, Sommergruber W, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P.

Diagn Mol Pathol. 2006 Mar;15(1):35-42.


Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.

Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P.

Cancer Immun. 2005 Aug 3;5:10.


FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor.

Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN.

Oncogene. 2004 Jul 15;23(32):5435-46.


Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.

Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, Obata Y, Stockert E, Hall CM, Old LJ, Rettig WJ, Scott AM.

Mol Cancer Ther. 2003 Aug;2(8):729-37.


A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.

Clin Cancer Res. 2003 May;9(5):1639-47.


Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.

Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, Garin-Chesa P.

J Invest Dermatol. 2003 Feb;120(2):182-8.


Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate.

Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A.

J Biol Chem. 2002 May 3;277(18):15566-72. Epub 2002 Feb 19.


A highly selective telomerase inhibitor limiting human cancer cell proliferation.

Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Müller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A.

EMBO J. 2001 Dec 17;20(24):6958-68.


Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.

Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D.

Mol Med. 2001 Jul;7(7):461-9.


Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium.

Christian S, Ahorn H, Novatchkova M, Garin-Chesa P, Park JE, Weber G, Eisenhaber F, Rettig WJ, Lenter MC.

J Biol Chem. 2001 Dec 21;276(51):48588-95. Epub 2001 Sep 14.


Expression of the fibroblast activation protein during mouse embryo development.

Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U, Rettig WJ, Schnapp A.

Int J Dev Biol. 2001 Apr;45(2):445-7.


Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.

Mersmann M, Schmidt A, Rippmann JF, Wüest T, Brocks B, Rettig WJ, Garin-Chesa P, Pfizenmaier K, Moosmayer D.

Int J Cancer. 2001 Apr 15;92(2):240-8.


Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.

Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM.

Br J Clin Pharmacol. 2001 Feb;51(2):177-80.


Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.

Schmidt A, Müller D, Mersmann M, Wüest T, Gerlach E, Garin-Chesa P, Rettig WJ, Pfizenmaier K, Moosmayer D.

Eur J Biochem. 2001 Mar;268(6):1730-8.


Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium.

Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ, Lenter MC.

J Biol Chem. 2001 Mar 9;276(10):7408-14. Epub 2000 Nov 17.


Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis.

Rippmann JF, Hobbie S, Daiber C, Guilliard B, Bauer M, Birk J, Nar H, Garin-Chesa P, Rettig WJ, Schnapp A.

Cell Growth Differ. 2000 Jul;11(7):409-16.


Targeted disruption of mouse fibroblast activation protein.

Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A.

Mol Cell Biol. 2000 Feb;20(3):1089-94.


Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.

Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ.

J Biol Chem. 1999 Dec 17;274(51):36505-12.


Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis.

Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD.

Hepatology. 1999 Jun;29(6):1768-78.


Mouse fibroblast-activation protein--conserved Fap gene organization and biochemical function as a serine protease.

Niedermeyer J, Enenkel B, Park JE, Lenter M, Rettig WJ, Damm K, Schnapp A.

Eur J Biochem. 1998 Jun 15;254(3):650-4.


One-step affinity purification protocol for human telomerase.

Schnapp G, Rodi HP, Rettig WJ, Schnapp A, Damm K.

Nucleic Acids Res. 1998 Jul 1;26(13):3311-3.


Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.

Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A.

Int J Cancer. 1997 May 2;71(3):383-9.


TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.

Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P.

J Urol. 1995 May;153(5):1575-9.


Human neuroblastoma I-type cells are malignant neural crest stem cells.

Ross RA, Spengler BA, Domènech C, Porubcin M, Rettig WJ, Biedler JL.

Cell Growth Differ. 1995 Apr;6(4):449-56.


Gene expression of tenascin is altered in normal scars and keloids.

Sible JC, Rettig WJ, Eriksson E, Smith SP, Oliver N.

Wound Repair Regen. 1995 Jan-Mar;3(1):37-48.


The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23.

Mathew S, Scanlan MJ, Mohan Raj BK, Murty VV, Garin-Chesa P, Old LJ, Rettig WJ, Chaganti RS.

Genomics. 1995 Jan 1;25(1):335-7. No abstract available.


Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily.

Campbell IG, Foulkes WD, Senger G, Trowsdale J, Garin-Chesa P, Rettig WJ.

Cancer Res. 1994 Nov 15;54(22):5761-5.


Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels.

Sanz-Moncasi MP, Garin-Chesa P, Stockert E, Jaffe EA, Old LJ, Rettig WJ.

Lab Invest. 1994 Sep;71(3):366-73.


Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.

Yoshikawa H, Rettig WJ, Lane JM, Takaoka K, Alderman E, Rup B, Rosen V, Healey JH, Huvos AG, Garin-Chesa P.

Cancer. 1994 Aug 1;74(3):842-7.


Fibroblast activation protein: purification, epitope mapping and induction by growth factors.

Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, Healey JH, Old LJ.

Int J Cancer. 1994 Aug 1;58(3):385-92.


Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.

Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61.


Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations.

Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, Garin-Chesa P.

Diagn Mol Pathol. 1994 Jun;3(2):83-92.


Functional identification of integrin laminin receptors that mediate process outgrowth by human SY5Y neuroblastoma cells.

Choi ES, Rettig WJ, Wayner EA, Srour ML, Clegg DO.

J Neurosci Res. 1994 Mar 1;37(4):475-88.


Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P, Boon T, Old LJ.

Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1004-8.


Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways.

Rettig WJ, Erickson HP, Albino AP, Garin-Chesa P.

J Cell Sci. 1994 Feb;107 ( Pt 2):487-97.


Differentiation-inducing agents stably convert human neuroblastoma I-type cells to neuroblastic (N) or nonneuronal (S) neural crest cells.

Ross RA, Spengler BA, Rettig WJ, Biedler JL.

Prog Clin Biol Res. 1994;385:253-9. No abstract available.


Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody.

Yoshikawa H, Rettig WJ, Takaoka K, Alderman E, Rup B, Rosen V, Wozney JM, Lane JM, Huvos AG, Garin-Chesa P.

Cancer. 1994 Jan 1;73(1):85-91.


EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression.

Ladanyi M, Lewis R, Garin-Chesa P, Rettig WJ, Huvos AG, Healey JH, Jhanwar SC.

Diagn Mol Pathol. 1993 Sep;2(3):141-6.


Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ.

Cancer Res. 1993 Jul 15;53(14):3327-35.


Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer.

Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ.

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10832-6.


Immunogenetics of cell surface antigens of human cancer.

Rettig WJ.

Curr Opin Immunol. 1992 Oct;4(5):630-40. Review.


Supplemental Content

Loading ...
Support Center